Posts Tagged ‘Ozempic’

GLP-1 Supply Issues: Both Companies on Their Toes?

November 3, 2023 — Novo Nordisk and Eli Lilly updated their investors yesterday on their performance through the third quarter of 2023 and the word is that they are “raking in cash” from their new medicines that work so well in obesity. Gobs of money seem to be flowing to both companies, but the stories they were telling about […]

Speculation About Ripples from Effective Obesity Treatment

October 28, 2023 — Oh my goodness. Wall Street is having waves of panic about the possibility that big food, big burrito, or big dialysis might not be able to keep selling us ever more of their services and stuff. For the last month we’ve been seeing ripples run through the stock market when investors started thinking maybe consumers […]

The GLP-1 Windfall for Pharmacy Benefit Managers

October 24, 2023 — We have grown tired of the mindless repetition of a $1,350 monthly list price for Wegovy in endless news reports about the great expense of this very important new drug for obesity. Not because the drug isn’t expensive. But because that list price is not an accurate representation of what the drug really costs. So […]

Reminder: Semaglutide Is Not DIY Weight Loss

September 29, 2023 — In case you haven’t been paying attention, FDA issued a new label warning for semaglutide that should remind everyone of a key fact – it’s not suitable for DIY weight loss. The warning went onto the label for the Ozempic brand of semaglutide. It is already there for the Wegovy brand and for the Mounjaro […]

Places with Wealth-Based Access to Diabetes and Obesity Care

August 27, 2023 — Writing for the New York Times, Joseph Goldstein tells us that prescriptions for GLP-1 agonists are going to the wealthiest, whitest, and healthiest neighborhoods in New York City. Neighborhoods where the medical need is greatest? Not so much. Though we might hope that advanced medicines for obesity and diabetes would go to places with the […]

High U.S. Drug Prices, High Obesity Rates, Twisted Economics

August 19, 2023 — The intersection of high U.S. drug prices with its high obesity rates is creating some unusual economics. Kaiser Family Foundation (KFF) and the Peterson Center on Healthcare released an analysis this week that brings this into sharp focus. The analysis tells us that published prices for GLP-1 medicines used for obesity and diabetes are the […]

Will Broader Access Beget Lower Prices for Obesity Meds?

July 10, 2023 — In thoughtful reporting for Fortune, Rachel Shin explores the possibility for broader access to advanced obesity meds leading to lower prices. But it’s a bit of a chicken-and-egg puzzle because it might be more likely that lower prices will lead to broader access. Novopoly Shin calls it a Novopoly. Novo Nordisk invested billions of dollars […]

Privilege, Stigma, and Better Obesity Care

June 8, 2023 — Typically, Ruth Marcus writes about justice for the Washington Post. But this week, she posted a very personal essay – “the most personal piece I have ever written” – about her experience with taking Ozempic. More than just a testimonial about the life-changing effects of better obesity care, it became an exploration of the interaction […]

Why Ozempic Gets More Traction Than Wegovy

April 26, 2023 — Insights surface when we take the time to listen to people living with obesity. Yesterday, Ro and the Obesity Action Coalition released results from a study of the thoughts and feelings people are having about obesity, weight loss, and the new GLP-1 medicines. There’s a lot to think about in these results – about motivations […]

The Merger of Obesity and Diabetes

April 3, 2023 — This is a merger that has taken decades – the merger of obesity and diabetes. Ethan Sims first coined the term diabesity in 1973. Even five decades ago, the coincidence of diabetes and obesity was unmistakable, but the standards of care for obesity and diabetes did not reflect the recognition of obesity as anything other […]